Scholarlink

<p>Parkinson’s disease (PD) has generated extensive mechanistic insight, yet nearly all candidate disease-modifying therapies have failed in clinical trials. Antibodies targeting α-synuclein, mitochondrial antioxidants, lysosomal interventions, and anti-inflammatory agents frequently achieve target engagement without slowing clinical progression, creating a central paradox in PD therapeutics.</p><p><?noindent??>Here we propose that this discrepancy arises because PD is not primarily a single-pathway neurodegenerative disorder but a multi-scale systems disease. Molecular pathology, organellar dysfunction, immune activation, and large-scale network instability form a self-reinforcing cascade in which interventions acting at a single biological level cannot substantially modify disease once degeneration is embedded within distributed neural circuits.</p><p><?noindent??>This framework generates testable predictions: pathway-targeted therapies may show benefit primarily in prodromal or biomarker-defined populations, whereas established clinical PD will likely require combination strategies coupling circuit restoration with axis-matched molecular interventions. Therapeutic responsiveness should therefore correlate more strongly with network integrity than with target engagement alone.</p><p><?noindent??>Viewing PD as a multi-scale systems disorder provides a unifying explanation for repeated therapeutic failures and offers a framework for biomarker-guided, stage-matched disease-modifying trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Parkinson’s disease as a multi-axis systems disorder: integrating molecular pathology and circuit-level therapeutics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月14日

查看全文
  • Duc-Hiep Bach,
  • Thanh Liem Nguyen

摘要

Parkinson’s disease (PD) has generated extensive mechanistic insight, yet nearly all candidate disease-modifying therapies have failed in clinical trials. Antibodies targeting α-synuclein, mitochondrial antioxidants, lysosomal interventions, and anti-inflammatory agents frequently achieve target engagement without slowing clinical progression, creating a central paradox in PD therapeutics.

Here we propose that this discrepancy arises because PD is not primarily a single-pathway neurodegenerative disorder but a multi-scale systems disease. Molecular pathology, organellar dysfunction, immune activation, and large-scale network instability form a self-reinforcing cascade in which interventions acting at a single biological level cannot substantially modify disease once degeneration is embedded within distributed neural circuits.

This framework generates testable predictions: pathway-targeted therapies may show benefit primarily in prodromal or biomarker-defined populations, whereas established clinical PD will likely require combination strategies coupling circuit restoration with axis-matched molecular interventions. Therapeutic responsiveness should therefore correlate more strongly with network integrity than with target engagement alone.

Viewing PD as a multi-scale systems disorder provides a unifying explanation for repeated therapeutic failures and offers a framework for biomarker-guided, stage-matched disease-modifying trials.